Abstract: Glycolysis, hypoxia, and proliferation are important factors in the tumor microenvironment contributing to treatment-resistant aggressiveness. Imaging these factors using combined functional positron emission tomography and computed tomography can potentially guide diagnosis and management of cancer patients. A dog with fibrosarcoma was imaged using 
were performed on consecutive days one week prior to the first radiotherapy fraction, after five and 10 fractions of radiotherapy, and finally at 10 weeks after the end of treatment.
The initial 18 F-FDG PET/CT scan data was used for the radiotherapy plan. The gross tumor volume (GTV) was delineated on the CT by cooperation between a veterinarian and an experienced radiologist. Furthermore, a specialist in nuclear medicine helped in incorporating the evaluation of the 18 F-FDG PET in the GTV.
All scans were performed on the same combined PET/CT scanner (Biograph40, Siemens, Munich, Germany) consisting of a 40-slice CT scanner and a high-resolution PET scanner. CT parameters were: 120 kV, 170 mAs, pitch 1.2, collimation 24 × 1.2 mm, slice thickness 3.0 mm, and a B30 kernel. PET scans were acquired using a three-dimensional (3D) acquisition mode and True X reconstruction (point spread function, three iterations, 21 subsets, Syngo MI. PET/CT 2008A, Siemens, Munich, Germany) and smoothed using a Gaussian filter having a full width at half maximum of 2 mm, and a matrix size of 336 × 336.
Radiotherapy was administered using a linear accelerator (Novalis Tx™, Varian Medical Systems, Inc., Palo Alto, CA, USA). Six MV photons were given as a conformal 3D field technique. ExacTrac X-ray 6D (BrainLab, Feldkirchen, Germany) and cone beam CT were used to ensure precise and uniform positioning.
The canine patient fasted for at least 12 h prior to all PET/CT scans and radiotherapy. Anesthesia during the procedures was induced with propofol (4 mg/kg, B. Braun Medical A/S, Frederiksberg, Denmark) after pre-medication with methadone (0.2-0.3 mg/kg i.m., Comfortan Vet 10 mg/mL, Dechra Veterinary Products A/S, Uldum, Denmark). Anesthesia was maintained using the continuous rate infusion of propofol (15-25 mg/kg/h) with 100% oxygen via an endo-tracheal tube. Heart rate, oxygen saturation, blood pressure, and CO2 concentrations were monitored throughout the anesthesia. During radiotherapy and PET/CT scans, the canine patient was positioned in a vacuum-fixed pillow to achieve precise and uniform positioning. Isocentric lasers and markers of copper wire were used to re-establish the correct patient position between individual scans and treatments.
Before each 18 F-FDG PET/CT scan, blood glucose measurements confirmed normal blood glucose levels. 18 F-FDG from daily routine productions for clinical use and 18 F-FLT produced as previously described [5] were produced at the Cyclotron Unit, Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital, Denmark.
64
Cu-ATSM was purchased from Hevesy Laboratory, DTU Campus Risø, Denmark.
All tracers were injected as an intravenous bolus of approximately 7.2 MBq/kg with slight variations between tracers and scans. Images from the same scan series were manually co-registered according to the CT images. PET uptake was quantified using the standardized uptake value (SUV), which is a unitless semi-quantitative measure that accounts for the injected dose and the body weight [6, 7] : SUV = Activity in tumor region (kBq/mL)/(Injected tracer activity (MBq)/body weight (kg))
Using the 18 F-FDG PET/CT scan and 3D iso-contouring in TrueD (Syngo, Multi Modality Workplace VE40A, Siemens, Munich, Germany), a tumor volume defined by a SUV cut-off on 2.5 ( The SUV cut-off on 2.5 was chosen since it has been used to discern between benign and malignant lesions when evaluating, for instance, lung and adrenal masses [8, 9] . Additionally, in soft tissue lesions, 18 F-FDG PET is good at differentiating between benign and malignant [10] . Furthermore, in studies of Ewing sarcomas and extremity osteosarcomas, a 18 F-FDG SUV value under 2.5 during scanning after neoadjuvant chemotherapy was predictive of progression-free survival [11, 12] .
Results and Outcome
Tumor uptake of Cu-ATSM PET/CT 6.5 h after intravenous injection. Pink angular lines demarcate 3D iso-contouring lines for the tumor volume of interest (VOI) defined by a standardized uptake value (SUV) cut-off at 2.5 for The hypo-fractionated radiotherapy was well tolerated, the formation of an acute superficial moist dermatitis in the radiation field being the only sign of acute radiotherapy injuries. During and post-treatment, the canine patient showed varying but reduced degrees of lameness on the left hind limb. Lameness commenced after the fourth radiotherapy fraction, but decreased in the third week post-radiotherapy. Lameness increased again approximately five weeks post-radiotherapy, but could be controlled therapeutically, and about three months post-radiotherapy, the lameness was mild and intermittent, but there was still soreness at full extension of the left stifle joint. Lameness was first managed using firocoxib (Previcox 227 mg, Merial Norden A/S, Hørsholm, Denmark) initiated at initial presentation, but due to renal complication, this was withdrawn 4.5 months post-radiotherapy, leading to increasing degrees of lameness and pain. Physiotherapy twice weekly and, later, daily pain treatment with meloxicam (Metacam 1.5 mg/mL; Boehringer Ingelheim DK A/S, Copenhagen, Denmark, 0.1 mg/kg) made the canine patient improve. At seven months post-radiotherapy, there was an acute deterioration with an acute lameness. A pathological tibial fracture was diagnosed and acute left hind limb amputation was recommended, but the owners decided to euthanize the canine patient.
Discussion
To the authors' knowledge, this pilot study is one of the first to illustrate the simultaneous use of three different PET/CT tracers for non-invasive functional imaging of molecular changes in a canine cancer patient before, during, and after radiotherapy. F-FDG PET uptakes. This is due to the fact that 18 F-FDG as a marker of glycolytic activity is not tumor-specific, but is also taken up by, for instance, macrophages during inflammation [13] . Inflammation during tissue remodeling may also account for the reduced but continued uptake of F-FLT is decreased at scanning 10 weeks after the end of therapy, perhaps an evaluation of the radiotherapy response in canine soft tissue sarcomas should not be done directly after completion of radiotherapy, but rather after waiting for some weeks.
The visual interpretation of the scan images revealed a heterogeneous spatial distribution of the three tracers, which to some extent was overlapping, though not identical. This indicates that additional information about tumor heterogeneity and treatment response is gained through multi-tracer imaging. The use of multiple tracers may also be beneficial for individualized treatment planning and to predict outcome, since more aspects of the tumor phenotype are elucidated. This is illustrated in a recent study which showed that 64 Cu-ATSM and 18 F-FDG provide different biological information to be taken into account when using dose painting for radiotherapy planning [14] . With dose painting, a non-uniform radiation dose distribution is prescribed to the target volume based on information from, for instance, PET scans on tumor areas that might be resistant and thus require a higher dose [15] . The aforementioned study focused on dose painting of hypoxic areas [14] , since tumor hypoxia has an essential impact on the molecular mechanisms in solid cancers by up-regulating multiple genes resulting in an aggressive phenotype and treatment resistance [16] . Though targeting hypoxic tumor areas is of great interest in the field of radiotherapy planning, other phenotypically distinct tumor areas such as highly proliferative areas delineated by 18 F-FLT PET may also be worth attending in future radiotherapy planning research.
Until recently, guidelines for evaluating solid tumors' responses to treatment relied on anatomical imaging techniques such as CT and MRI (RECIST) [17, 18] . Since 18 F-FDG PET/CT has shown promising results for response monitoring during treatment in different human cancers [19] , new guidelines using 18 F-FDG PET/CT have emerged (PERCIST) [20] . Likewise, 18 F-FLT has shown promising results for early response monitoring in human head and neck cancer [21, 22] . Precisely the use of these two PET/CT tracers for response monitoring after radiotherapy in canine cancer patients was first published in a case report where 18 F-FLT PET/CT in supplement to 18 F-FDG revealed disease recurrence [23] . During the last two years, a couple of interesting canine studies have followed. A study of 10 canine patients with sinonasal cancers (seven adenocarcinomas, a chondrosarcoma, a osteosarcoma, and a squamous cell carcinoma) used pre-treatment Cu-ATSM PET uptake did not contribute significantly to multivariate regression coefficients [24] . This study is, however, limited by the absence of follow-up PET/CT scans with Cu-ATSM during PET/CT in a cohort of 22 canine patients with sinonasal cancers, eight of which were sarcomas [25] . They found a significantly greater overlap between the highest uptake volumes of the three tracers in carcinomas than in sarcomas, a finding comparable to the visual interpretations of our PET/CT images in a canine fibrosarcoma. A more recent study of the same canine cohort investigating the changes in Cu-ATSM PET uptakes between pre-treatment and mid-treatment PET/CT scans during hypo-fractionated radiotherapy showed a significant reduction in the 61 Cu-ATSM uptake after three fractions of intensity-modulated radiation therapy (IMRT) (12.6 or 15 Gy) in carcinomas, but not in sarcomas [26] . The reduction in 18 F-FLT PET uptake after two fractions of IMRT (8.4 or 10 Gy) was significant for both tumor types [26] . Visual interpretation of our PET/CT scan results in Figure 1 show a similar tendency as the 18 F-FLT PET uptake is reduced more than the 64 Cu-ATSM PET uptake from pre-treatment to mid-treatment, though keeping in mind that our mid-treatment scan is first performed after 22.5 Gy and the 64 Cu-ATSM scan is performed approximately 6.5 h after injection and not 3 h, as Bradshaw et al. used in their study [26] . A recent study of changes in dynamic 18 F-FDG PET/CT and contrast-enhanced cone beam CT between pre-, mid-, and post-treatment scans during IMRT (40-46 Gy in 10 fractions) of three canine patients with spontaneous head and neck tumors illustrated the attractiveness of doing multi-modal, multi-parameter imaging for evaluating therapy-induced tumor modifications [27] . This study, however, like ours, only included a very limited number of patients. Therefore, further studies are necessary before the incorporation of multiple expensive PET tracers in routine treatment response monitoring might become a reality.
Taken together, our pilot study has presented unique data regarding the simultaneous use of multiple tracers for response monitoring. Using more than one tracer reveals potentially important information about tumor heterogeneity. It is apparent from our study as well as the other studies discussed that different tracers contribute distinctive information about the tumor phenotype, information that may differ between different histopatologic cancer types, as the studies by Bradshaw et al. showed [25, 26] . Furthermore, being markers of different molecular pathways within the tumor cells and their microenvironment, the individual tracers respond diversely to treatment, as seen in our study. Thus, each tracer adds unique information when using more than one tracer for response monitoring. Further investigations including more canine patients are, however, necessary to elucidate the true value and benefits of using a combination of 18 F-FDG, 18 F-FLT, and 64 Cu-ATSM PET/CT when monitoring response during radiotherapy and to verify the exact significance of using these tracers for individualized treatment planning. Another important aspect to consider is how to interpret the sum of information gained through multi-tracer imaging, and also further study which scan time points are most relevant for response evaluation and prediction of outcome.
Since the biological features of canine cancers resemble human cancers and similar therapies are used for solid tumors in dog and man, further canine studies evaluating multi-tracer PET/CT for therapy planning and response monitoring may give valuable information for both canine and human patients.
